-
3-tert-butyl-1-[6-(2,6-dichlorophenyl)-2-{[4-(diethylamino)butyl]amino}pyrido[2,3-d]pyrimidin-7-yl]urea
-
ChemBase ID:
154704
-
Molecular Formular:
C26H35Cl2N7O
-
Molecular Mass:
532.5084
-
Monoisotopic Mass:
531.22801414
-
SMILES and InChIs
SMILES:
CCN(CC)CCCCNc1ncc2cc(c(nc2n1)NC(=O)NC(C)(C)C)c1c(cccc1Cl)Cl
Canonical SMILES:
CCN(CCCCNc1ncc2c(n1)nc(c(c2)c1c(Cl)cccc1Cl)NC(=O)NC(C)(C)C)CC
InChI:
InChI=1S/C26H35Cl2N7O/c1-6-35(7-2)14-9-8-13-29-24-30-16-17-15-18(21-19(27)11-10-12-20(21)28)23(31-22(17)32-24)33-25(36)34-26(3,4)5/h10-12,15-16H,6-9,13-14H2,1-5H3,(H3,29,30,31,32,33,34,36)
InChIKey:
MKVMEJKNLUWFSQ-UHFFFAOYSA-N
-
Cite this record
CBID:154704 http://www.chembase.cn/molecule-154704.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
3-tert-butyl-1-[6-(2,6-dichlorophenyl)-2-{[4-(diethylamino)butyl]amino}pyrido[2,3-d]pyrimidin-7-yl]urea
|
|
|
IUPAC Traditional name
|
3-tert-butyl-1-[6-(2,6-dichlorophenyl)-2-{[4-(diethylamino)butyl]amino}pyrido[2,3-d]pyrimidin-7-yl]urea
|
|
|
Synonyms
|
1-tert-Butyl-3-[6-(2,6-dichlorophenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]urea
|
PF-1480232
|
PD-161570
|
N-[6-(2,6-Dichlorophenyl)-2-[[4-(diethylamino)butyl]amino]pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea
|
1-Tert-butyl-3-[6-(2,6-dichloro-phenyl)-2-(4-diethylamino-butylamino)pyrido[2,3-d]pyrimidin-7-yl]urea
|
PD-161570
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
11.504685
|
H Acceptors
|
6
|
H Donor
|
3
|
LogD (pH = 5.5)
|
2.117705
|
LogD (pH = 7.4)
|
2.8022866
|
Log P
|
5.4242797
|
Molar Refractivity
|
152.6838 cm3
|
Polarizability
|
58.128258 Å3
|
Polar Surface Area
|
95.07 Å2
|
Rotatable Bonds
|
10
|
Lipinski's Rule of Five
|
false
|
DETAILS
DETAILS
Sigma Aldrich
TRC
Sigma Aldrich -
PZ0109
|
Biochem/physiol Actions PD-161570 is an inhibitor of human FGF-1 receptor tyrosine kinase. Legal Information Sold for research purposes under agreement from Pfizer Inc. |
Toronto Research Chemicals -
P217490
|
A novel FGF-1 receptor tyrosine kinase inhibitor which has been shown to effectively suppress constitutive phosphorylation of the FGF-1 receptor in human ovarian carcinoma cells. |
PATENTS
PATENTS
PubChem Patent
Google Patent